Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
确定百岁老人的保护性组学特征并将其转化为预防和治疗策略
基本信息
- 批准号:10449626
- 负责人:
- 金额:$ 33.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Administrative SupplementAntibodiesBindingBiologicalBiological AssayBloodCentenarianChargeCollaborationsCollectionComputing MethodologiesCoupledDataDetectionEnrollmentFamily StudyFundingGenerationsGoalsHumanInfrastructureLabelLifeLongevityMainstreamingMass Spectrum AnalysisMeasurementMethylationParentsPerformancePhasePhenotypePopulationPreparationPreventivePropertyProteinsProteomeProteomicsProvinceQuality ControlReagentSamplingSensitivity and SpecificitySerumSpecificityTechnologyTherapeuticTranslatinganalysis pipelineaptamerbasecohortdata managementdesigndosageexperimental studyhead-to-head comparisonhealthy agingmetabolomicsmicrobiome researchmultiple omicsnext generation sequencingoffspringparent grantparent projectphenotypic dataprotein profilingrecruittranscriptomics
项目摘要
Assessing accuracy of protein measurements across multiple analytical platforms. Our NIA funded
project, UH2AG064704 “Identifying protective omics profiles in centenarians and translating these into
preventive and therapeutic strategies”, is a phased UH2/UH3 project. We are currently in the UH2 phase, in
which we achieve specific milestones to set the stage for and facilitate the conduct of the UH3 phase. Among
the major UH2 milestones, we are recruiting and enrolling 1,400 centenarians and their offspring, and we are
collecting their phenotype data, blood and fecal samples. In the UH3 phase, we will generate multi-omics
profiles of those samples and correlate them with extreme human longevity phenotypes. Other major
milestones of the UH2 phase include planning for the generation of omics data and developing analyses
pipelines that we will use in the UH3 phase of the project. We have made substantial progress toward
enrollment, data management, and plans for the majority of omics data and we also realized the importance of
using an accurate data generating platform that is well harmonized with those used by other studies of human
extreme longevity such as the Long Life Family Study and the Longevity Consortium. In our parent application,
we proposed to use the SOMAscan technology to generate serum proteomics. Alternative proteomics
approaches include labelled mass spectrometry and the Olink Explore platforms. These three mainstream
technologies have pros and cons in terms of required sample preparation, coverage of the human proteome,
accuracy of protein abundance assessment, and specificity of proteins detection and their performance has not
been compared in a comprehensive way. In this request for an administrative supplement we propose to
generate data that will inform the choice of the best proteomic platform to be used in the UH3 phase of the
project. We have the opportunity to join forces with other studies of human extreme longevity to compare mass
spectrometry, SOMAscan and Olink platforms using a well-designed spike-in experiment. We propose two
specific aims. Specific Aim 1: To generate SOMAlogic-based proteomic profiles of 250 samples that
represent triplicates of one control condition, and 6 pools including 8 different proteins spiked at 13 different
abundance, for a total of 3 + 3𝑥6𝑥13 = 237 samples. We will add an additional 13 blank samples for quality
control. Specific Aim 2: To conduct quality control analysis of the proteomic profiles generated using the
SOMAscan, Olink and Mass-spectrometry technologies. Cleaned and normalized data will be used to analyze
the dosage-based trajectories of protein abundance to detect proteins that change in the different pools and to
estimate sensitivity and specificity of protein detection of the SOMAscan, Olink and mass-spectrometry
technologies. The comparison of data generated with the Somascan technology versus alternative technology
will provide critical information to guide the selection of the best proteomic technology to use in the UH3 phase
of the parent project.
在多个分析平台上评估蛋白质测量的准确性。我们的NIA资助了
项目,UH 2AG 064704“确定百岁老人的保护组学概况,并将其转化为
预防和治疗战略”是一个分阶段的UH 2/UH 3项目。我们目前处于UH 2阶段,
我们实现了具体的里程碑,为UH 3阶段的进行奠定了基础并促进了该阶段的进行。之间
主要的UH 2里程碑,我们正在招募和登记1,400名百岁老人和他们的后代,我们是
收集它们的表型数据、血液和粪便样本。在UH 3阶段,我们将生成多组学
并将它们与极端的人类长寿表型相关联。其他主要
UH 2阶段的里程碑包括计划生成组学数据和开发分析
我们将在项目的UH 3阶段使用的管道。我们已经取得了实质性的进展,
注册,数据管理和计划的大部分组学数据,我们也意识到的重要性
使用准确的数据生成平台,该平台与其他人类研究所使用的平台协调一致。
例如长寿家庭研究和长寿联盟。在我们的父应用程序中,
我们建议使用SOMAscan技术来产生血清蛋白质组。替代蛋白质组学
这些方法包括标记质谱法和Olink Explore平台。这三个主流
技术在所需的样品制备,人类蛋白质组的覆盖范围,
蛋白质丰度评估的准确性和蛋白质检测的特异性及其性能还没有
进行了全面的比较。在这一行政补充请求中,我们建议
生成的数据,将告知选择最好的蛋白质组学平台,用于UH 3阶段的
项目我们有机会与其他关于人类极端长寿的研究联合起来,
使用精心设计的加标实验,在光谱法、SOMAscan和Olink平台上进行。我们提出了两
具体目标。具体目标1:生成250个样本的基于SOMAlogic的蛋白质组学图谱,
代表一种对照条件的一式三份,6个样本池包括8种不同的蛋白质,以13种不同的浓度加标
丰度,总共3 + 3× 6× 13 = 237个样品。我们将增加额外的13个空白样品的质量
控制具体目标2:对使用
SOMAscan、Olink和质谱技术。将使用经过清理和规范化的数据进行分析
基于剂量的蛋白质丰度轨迹,以检测不同库中变化的蛋白质,
评估SOMAscan、Olink和质谱法蛋白质检测的灵敏度和特异性
技术. Somascan技术与替代技术生成的数据比较
将提供关键信息,以指导选择最佳蛋白质组学技术用于UH 3阶段
的父项目。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Protein cost minimization promotes the emergence of coenzyme redundancy.
- DOI:10.1073/pnas.2110787119
- 发表时间:2022-04-05
- 期刊:
- 影响因子:11.1
- 作者:
- 通讯作者:
Bayesian differential analysis of cell type proportions: opinion.
- DOI:10.3389/fgene.2023.1205499
- 发表时间:2023
- 期刊:
- 影响因子:3.7
- 作者:Karagiannis, Tanya T.;Monti, Stefano;Sebastiani, Paola
- 通讯作者:Sebastiani, Paola
Cell Type Diversity Statistic: An Entropy-Based Metric to Compare Overall Cell Type Composition Across Samples.
- DOI:10.3389/fgene.2022.855076
- 发表时间:2022
- 期刊:
- 影响因子:3.7
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS T PERLS其他文献
THOMAS T PERLS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS T PERLS', 18)}}的其他基金
Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
确定百岁老人的保护性组学特征并将其转化为预防和治疗策略
- 批准号:
10017131 - 财政年份:2019
- 资助金额:
$ 33.78万 - 项目类别:
Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
确定百岁老人的保护性组学特征并将其转化为预防和治疗策略
- 批准号:
10678171 - 财政年份:2019
- 资助金额:
$ 33.78万 - 项目类别:
Protein Signatures of APOE2 and Cognitive Aging
APOE2 的蛋白质特征和认知衰老
- 批准号:
10451539 - 财政年份:2018
- 资助金额:
$ 33.78万 - 项目类别:
Protein Signatures of APOE2 and Cognitive Aging
APOE2 的蛋白质特征和认知衰老
- 批准号:
10219143 - 财政年份:2018
- 资助金额:
$ 33.78万 - 项目类别:
Protein Signatures of APOE2 and Cognitive Aging
APOE2 的蛋白质特征和认知衰老
- 批准号:
10408304 - 财政年份:2018
- 资助金额:
$ 33.78万 - 项目类别:
相似海外基金
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10454419 - 财政年份:2021
- 资助金额:
$ 33.78万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10672258 - 财政年份:2021
- 资助金额:
$ 33.78万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10293635 - 财政年份:2021
- 资助金额:
$ 33.78万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 33.78万 - 项目类别:
Studentship
Covalent binding Antibodies as a Chemical Tool to Probe Immune Molecular Recognition
共价结合抗体作为探测免疫分子识别的化学工具
- 批准号:
565778-2021 - 财政年份:2021
- 资助金额:
$ 33.78万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Establishment of a novel serum diagnosis method for flaviviruses based on binding profiles of anti-flavivirus antibodies
基于抗黄病毒抗体结合谱建立黄病毒新型血清诊断方法
- 批准号:
20J22269 - 财政年份:2020
- 资助金额:
$ 33.78万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of Antigen Glycosylation in Mucin Binding by Monoclonal Antibodies
抗原糖基化在单克隆抗体粘蛋白结合中的作用
- 批准号:
10045898 - 财政年份:2020
- 资助金额:
$ 33.78万 - 项目类别:
Do anti-DNA antibodies play a role in the pathogenesis of systemic lupus erythematosus by binding/entering live cells?
抗 DNA 抗体是否通过结合/进入活细胞在系统性红斑狼疮的发病机制中发挥作用?
- 批准号:
16K08929 - 财政年份:2016
- 资助金额:
$ 33.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
N-Terminally fluorescent-labeled antibodies that show fluorescence change upon antigen-binding
N 末端荧光标记抗体,在抗原结合时显示荧光变化
- 批准号:
15K13739 - 财政年份:2015
- 资助金额:
$ 33.78万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
(i) Identification of single-molecule protein complexes involved in cellular transport of prosthetic groups (Moco and heme) (ii) Generation of monoclonal antibodies directed against protein motifs involved in binding prosthetic groups
(i) 鉴定参与假体基团(Moco 和血红素)细胞运输的单分子蛋白复合物 (ii) 生成针对参与结合假体基团的蛋白基序的单克隆抗体
- 批准号:
226653713 - 财政年份:2012
- 资助金额:
$ 33.78万 - 项目类别:
Research Units